HartungHPAktasOBoykoAN. Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis. Mult Scler J2015; 21(1): 22–34.
2.
ColesAJCohenJAFoxEJ, et al. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. Neurology2017; 89: 1117–1126.
3.
PhelpsRWinstonJAWynnD, et al. Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis. Mult Scler J2019; 25(9): 1273–1288.
4.
CukerABassADNadjC, et al. Immune thrombocytopenia in alemtuzumab treated-MS patients: Incidence, detection, and management. Mult Scler J2019; 26: 48–56.
5.
WraySHavrdovaESnydmanDR, et al. Infection risk with alemtuzumab decreases over time: Pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. Mult Scler J2018; 25: 1605–1617.
6.
WiendlHCarrariMComiG, et al. Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab. Neurol Neuroimmunol Neuroinflamm2020; 7: e635.
7.
ZappuloEBuonomoARSaccaF, et al. Incidence and predictive risk factors of infective events in patients with multiple sclerosis treated with agents targeting CD20 and CD52 surface antigens. Open Forum Infect Dis2019; 6(11): ofz445.
8.
FerraroDCameraVVitettaF, et al. Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis. Neurology2018; 90(18): 852–854.
9.
Durand-DubiefFMarignierRBerthezeneY, et al.Spontaneous multiple cervical artery dissections after alemtuzumab. Mult Scler J2020; 26(3): 381–383.
10.
AzevedoCJKutzCDixA, et al. Intracerebral haemorrhage during alemtuzumab administration. Lancet Neurol2019; 18(4): 329–331.
11.
AhrabianDNeillLBellR, et al. Acute cardiotoxicity associated with alemtuzumab infusion for multiple sclerosis. Mult Scler2020; 26(6): 735–737.
12.
MuraroPAScoldingNJFoxRJ, et al. Rare side effects of alemtuzumab remind us of the need for postmarketing surveillance. Neurology2018; 90: 819–820.
13.
DevonshireVPhillipsRWassH, et al. Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: Practical recommendations. J Neurol2018; 265(11): 2494–2505.
